" class="no-js "lang="en-US"> Pfizer Archives - Page 4 of 5 - Medtech Alert
Saturday, September 13, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease | MTA

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Read more

Drug Development

 Xeljanz ® (Tofacitinib Citrate) Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis | Pharmtech Focus

Xeljanz ® (Tofacitinib Citrate) Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has approved XELJANZ ® (tofacitinib) […]

COVID-19

 Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of Covid-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S. | Pharmtech Focus

Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of Covid-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. government […]

COVID-19

 Pfizer and BioNTech Announce Collaboration with Biovac to Manufacture and Distribute COVID-19 Vaccine Doses within Africa | Pharmtech Focus

Pfizer and BioNTech Announce Collaboration with Biovac to Manufacture and Distribute COVID-19 Vaccine Doses within Africa

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a letter of intent […]

Appointments

 Pfizer Announces New Investor Relations Leader | Pharmtech Focus

Pfizer Announces New Investor Relations Leader

Pfizer Inc. (NYSE: PFE) today announced that Christopher Stevo has joined the company as Senior […]

Diseases

 U.S. FDA Approves Prevnar 20™

U.S. FDA Approves Prevnar 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older

Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved […]

COVID-19

 The MHRA Concludes Positive Safety Profile for Pfizer/BioNTech Vaccine in 12- to 15-year-olds | Pharmtech Focus

The MHRA Concludes Positive Safety Profile for Pfizer/BioNTech Vaccine in 12- to 15-year-olds

An extension to the current UK approval of the Pfizer/BioNTech COVID-19 vaccine that allows its […]

COVID-19

 Pfizer Initiates Study Exploring Coadministration of 20vPnC Vaccine Candidate | Pharmtech Focus

Pfizer Initiates Study Exploring Coadministration of 20vPnC Vaccine Candidate

Pfizer Inc. (NYSE: PFE) today announced that the first enrolled subjects have received their immunizations as […]

COVID-19

 Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents | Pharmtech Focus

Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food […]

COVID-19

 Pfizer and BioNTech Initiate BLA for FDA Approval of Vaccine | Pharmtech Focus

Pfizer and BioNTech Initiate BLA for FDA Approval of Vaccine

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a Biologics License Application […]

COVID-19

 Pfizer and BioNTech to Provide COVID-19 Vaccine Doses for Olympic Athletes at the 2020 Tokyo Games | Pharmtech Focus

Pfizer and BioNTech to Provide COVID-19 Vaccine Doses for Olympic Athletes at the 2020 Tokyo Games

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a Memorandum of Understanding […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients

    Clinical Trials

     Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS

    Clinical Trials

     Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board

    Appointments

     Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera

    News

     Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic

    Clinical Trials

     Read more